Log in using OpenID

Global Oncology Drugs Market

Oncology drugs and medications have become a blooming business for players in the pharmaceutical industry.
Global Oncology Drugs Market - Competitive
Analysis And Revenue Growth
Oncology drugs and medications have become a blooming business for players in the
pharmaceutical industry. Major pharmaceutical companies are focused on manufacturing and
development of oncology drug. Market players have oncology drugs in pipeline, which are
expected to be in the market as potential medications in near future. Also, the global oncology
market is expected to gain a significant traction with the increasing prevalence of cancer.
According to the National Cancer Institute, cancer is among the leading causes of death
worldwide, which accounted for around 14 million new cases and 8.2 million cancer-related
deaths in 2012. The number of new cancer cases is projected to rise to 22 million in near
future. The major competitors are focused on developing efficient treatment for specific type of
cancer which is expected to be a prominent factor to augment the global oncology drugs
Request Sample Copy of Research Report @
Major manufacturers in the oncology drugs market include:
• Roche
• Celgene
• Johnson & Johnson
• Pfizer
• Sanofi
• Bristol-Meyers Squibb
• Novartis
• GlaxoSmithKline
• Eli Lily
• Merck & Co.
Top 5 company described for competitive analysis in detail:
1. Roche is a world leader in oncology, which is engaged in developing new approaches for
advanced cancer treatment. Roche operates in two segments, which includes
pharmaceuticals and diagnostics with annual sales of US$ 39.1 Bn and US$ 11.5 Bn
respectively. Roche is at the forefront of cancer immunotherapy with ten investigational
drug candidates currently in the clinical development phase. In 2016, the company
entered into 10 new clinical collaboration agreements to explore drug combinations for
maximizing therapeutic benefits and develop the lead immunotherapy drug. The company
has set up imCORE, a network of 21 academic institutions working with Roche to
advance research into cancer immunotherapies, thus contributing to enhance the global
oncology drugs market in the near future.
2. Johnson and Johnson operates in three business segments namely consumer,
pharmaceutical and medical devices. The business of Johnson & Johnson is conducted by
more than 230 operating companies located in 60 countries worldwide. In 2016, the
company has invested around US$ 9.1 Bn in research and development activities.
Janssen, the pharmaceutical division of J&J registered the oncology drug sales of around
US$ 5.9 Bn among the total pharmaceutical therapeutic area sales. Janssen is focused on
strategic collaborations for the development of cancer therapeutics, which in turn favors
the oncology drugs market. For instance, in November, 2017, Janssen collaborated with
Zymeworks, Inc. to develop six bispecific antibodies based on Azymetric and Effector
Function Enhancement and Control Technology (EFECT) platforms for research,
development, and commercialization with a potential to generate US$ 1.5 Bn. High sales
of IMBRUVICA (ibrutinib) and DARZALEX (daratumumab) were due to increasing patient
uptake, additional country launches, and additional indications, which contributed to the
growth of oncology drugs.
3. Pfizer, Inc. develops oncology therapies that provide maximum efficacy while minimizing
adverse effects on the patient. The current portfolio of oncology drugs covers a range of
cancers. The company studies these therapies alone and in combination with other
treatments to improve the lives of cancer patients. Pfizer’s overall strategy is anchored on
innovation for developing new medicines and vaccines through collaborations and
business relationships which is expected to bolster the oncology drugs market. For
instance, Pfizer partnered with Merck KGaA for building a strong portfolio in immunooncology, Biolnvent International AB to develop antibodies to advance the novel
technology platform of cancer vaccine as well as business relationship with IBM Watson
for drug discovery by identifying potential new targets and combination therapies in
4. Novartis’s aims to develop approaches for extending the lives of people suffering from
cancer, by adopting the strategy to use science-based innovation for delivering better
patient outcomes in growing areas of healthcare. Novartis operates in two business
segments namely Novartis Oncology and Novartis Pharmaceuticals, which together form
Innovative Medicines Division. The Novartis Oncology segment contributed around 39% of
its net sales, it was valued around US$ 12.8 Bn. Increase in revenue is attributed to the
strong performance for oncology products Tafinlar + Mekinist, a combination therapy for
advanced melanoma, and Jakavi, for blood cancers. Novartis is leading provider of cancer
treatments, following the acquisition of oncology products from GlaxoSmithKline in 2015.
In 2016, the company collaborated with Surface Oncology to bolster the cancer
immunotherapy pipeline that will provide access to four preclinical programs. Also, with
a licensing agreement with Xencor, it plans to co-develop two bispecific antibodies
designed to target acute myeloid leukemia and B-cell malignancies, thereby aiding the
growth of oncology drugs market.
Sanofi operates through two business segments namely pharmaceuticals and vaccines. Sanofi
gains insights through its network of collaborations with biotech companies such as Immunogen
and Evotec, academic cancer centers such as Institut Gustave Roussy, Institut Curie, and the
Dana Farber Cancer Institute, enabling superior use of software, analytics, and new technology,
which helps to increase its productivity, maximize return on R&D investment, and accelerate
the development of new products. Sanofi Oncology has a large number of collaborations and
alliances to support its R&D portfolio. In 2015, Sanofi collaborated with Regeneron focusing on
cancer immunotherapy to generate high value development candidates in the emerging field of
immuno-oncology and to accelerate its development pipeline in the oncology drugs market. In
2016, the company entered into a collaboration with Innate Pharma to develop innovative
bispecific antibody formats engaging natural killer (NK) cells to kill tumor cells. Also, it
collaborated with Warp Drive Bio to develop drugs targeting human oncogenes, thus
accelerating the innovations for oncology drugs.
Report includes chapters which deeply display the following deliverable about industry :
• Global Oncology Drugs Market Research Objective and Assumption
• Global Oncology Drugs Market Purview - Report Description, Executive Summary, and
Coherent Opportunity Map (COM)
• Global Oncology Drugs Market Dynamics, Regulations, and Trends Analysis - Market
Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Global Oncology Drugs Market , By Regions
• Global Oncology Drugs Market Competition by Manufacturers including Production, Share,
Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Global Oncology Drugs Market Manufacturers Profiles/Analysis including Company Basic
Information, Manufacturing Base and Its Competitors.
• Global Oncology Drugs Market Manufacturing Cost Analysis including Key Raw Materials and
Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Global Oncology Drugs Market Forecast including Production, Consumption, Import and
Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Inquire Here Before Purchase of Research Report @
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Alex Huge
Alex Huge414   documents Email
Health and Medicine
File Size
141 KB
oncology, Global Oncology Drugs Market
Report inappropriate content